Pharmafile Logo

Biolojic Design

- PMLiVE

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

Eli Lilly HQ

Baricitinib delay casts a pall over Lilly’s results update

FDA requests further data that could keep the drug off the market for a couple of years

Eli Lilly HQ

Lilly pays Nektar $150m upfront for phase I autoimmune drug

Will add another $250m if candidate meets development objectives

Roche acquires digital diabetes management platform

Will integrate mySugr within its new patient-centred health services arm

National Institute for Health and Care Excellence NICE logo

NICE backs Lilly’s rheumatoid arthritis drug Olumiant

The drug will be used alongside methotrexate to treat adults with severe, active RA

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

- PMLiVE

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm's ‘Behind The Smile’ initiative coincides with RA awareness week

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

Eli Lilly HQ

FDA fast-tracks Pfizer and Lilly’s tanezumab

The novel pain drug treats osteoarthritis and chronic low back pain

- PMLiVE

Trial of J&J’s canagliflozin boosts SGLT2 cardiovascular credentials

Invokana cuts risk of heart failure hospitalisation by a third

- PMLiVE

Novo says real-world data backs its insulin switching

EU-TREAT study shows Tresiba improved blood glucose control

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links